Medical Design and Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech

Xanodyne Agrees to Withdraw Propoxyphene From the U.S. Market

November 19, 2010 By Bio-Medicine.Org

SILVER SPRING, Md., Nov. 19, 2010 /PRNewswire-USNewswire/ —
Xanodyne Pharmaceuticals Inc., which makes Darvon and Darvocet, the
brand version of the prescription pain medication propoxyphene, has
agreed to withdraw the medication from the U.S. market at the
request of the U.S. Food and Drug Administration. The FDA has also
informed generic manufacturers of Xanodyne’s decision and they will
be removing their propoxyphene-containing products from the market
as well.

(Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO)

The FDA sought market withdrawal of propoxyphene after
receiving new clinical data showing that the drug puts patients at
risk of potentially serious or even fatal heart rhythm
abnormalities. As a result of these data, combined with other
information, including new epidemiological data, the agency
concluded that the risks of the medication outweigh the
benefits.  

“FDA is pleased by Xanodyne’s decision to voluntarily remove its
products from the U.S. market,” said John Jenkins, M.D., director
of the Office of New Drugs in the FDA’s Center for Drug Evaluation
and Research (CDER). “These new heart data significantly alter
propoxyphene’s risk-benefit profile. The drug’s effectiveness in
reducing pain is no longer enough to outweigh the drug’s serious
potential heart risks.”

The FDA is advising health care professionals to stop
prescribing propoxyphene to their patients, and patients who are
currently taking the drug should contact their health care
professional as soon as possible to discuss switching to another
pain management therapy.

Propoxyphene is an opioid used to treat mild to moderate pain.
First approved by the FDA in 1957, propoxyphene is sold by
prescription under various names both alone (e.g., Darvon) or in
combination with acetaminophen (e.g., Darvocet).

Since 1978, the FDA has received two requests to remo

‘/>”/>

SOURCE

Related Articles Read More >

CeQur Simplicity
CeQur is launching a discreet, convenient ‘wearable insulin pen’
Blackrock's Utah array is a miniature array of electrodes for sensing brain signals
Blackrock Neurotech and Pitt work on first at-home BCI system for remote trials
Engineer inspecting artificial hip joint parts in quality control department in orthopaedic factory
Deburring and finishing for beautiful, functional medical devices
A Medtronic HVAD pump opened up to show the inner workings
FDA designates new Medtronic HVAD pump implant recall as Class I

DeviceTalks Weekly.

July 1, 2022
Boston Scientific CEO Mike Mahoney on building a corporate culture that drives high growth results
See More >

MDO Digital Edition

Digital Edition

Subscribe to Medical Design & Outsourcing. Bookmark, share and interact with the leading medical design engineering magazine today.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
DeviceTalks

DeviceTalks is a conversation among medical technology leaders. It's events, podcasts, webinars and one-on-one exchanges of ideas & insights.

DeviceTalks

New MedTech Resource

Medical Tubing

Enewsletter Subscriptions

Enewsletter Subscriptions

MassDevice

Mass Device

The Medical Device Business Journal. MassDevice is the leading medical device news business journal telling the stories of the devices that save lives.

Visit Website
MDO ad
Medical Design and Outsourcing
  • MassDevice
  • DeviceTalks
  • MedTech 100 Index
  • Medical Tubing + Extrusion
  • Drug Delivery Business News
  • Drug Discovery & Development
  • Pharmaceutical Processing World
  • R&D World
  • About Us/Contact
  • Advertise With Us
  • Subscribe to Print Magazine
  • Subscribe to E-newsletter
  • Attend our Monthly Webinars
  • Listen to our Weekly Podcasts
  • Join our DeviceTalks Tuesdays Discussion

Copyright © 2022 WTWH Media, LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media LLC. Site Map | Privacy Policy | RSS

Search Medical Design & Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech